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ABSTRACT
Introduction There is an urgent need to reduce the
burden of non-communicable diseases (NCDs), particularly
in low-and middle-income countries, where the greatest
burden lies. Yet, there is little research concerning the
specific issues involved in scaling up NCD interventions
targeting low-resource settings. We propose to examine
this gap in up to 27 collaborative projects, which were
funded by the Global Alliance for Chronic Diseases (GACD)
2019 Scale Up Call, reflecting a total funding investment
of approximately US$50 million. These projects represent
diverse countries, contexts and adopt varied approaches
and study designs to scale-up complex, evidence-based
interventions to improve hypertension and diabetes
outcomes. A systematic inquiry of these projects will
provide necessary scientific insights into the enablers and
challenges in the scale up of complex NCD interventions.
Methods and analysis We will apply systems thinking (a
holistic approach to analyse the inter-relationship between
constituent parts of scaleup interventions and the context
in which the interventions are implemented) and adopt
a longitudinal mixed-methods study design to explore

Strengths and limitations of this study
► The Global Alliance for Chronic Disease 2019 Scale-

up Call provides a unique opportunity to systematically study up to 27 funded scale-up projects
in non-communicable diseases being rolled out in
low and middle-income countries and other low-
resource settings.
► The study team is independent of the scale-up project teams and this will help minimise any conflict of
interest that may potentially exist.
► Feedback about the common challenge due to
COVID-
19 pandemic may overshadow any other challenges that may have existed in scale-up
implementation.
the planning and early implementation phases of scale
up projects. Data will be gathered at three time periods,
namely, at planning (TP), initiation of implementation (T0)
and 1-year postinitiation (T1). We will extract project-
related data from secondary documents at TP and conduct
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multistakeholder qualitative interviews to gather data at T0 and T1. We
will undertake descriptive statistical analysis of TP data and analyse T0
and T1 data using inductive thematic coding. The data extraction tool and
interview guides were developed based on a literature review of scale-up
frameworks.
Ethics and dissemination The current protocol was approved by the
Monash University Human Research Ethics Committee (HREC number
23482). Informed consent will be obtained from all participants. The study
findings will be disseminated through peer-reviewed publications and
more broadly through the GACD network.

INTRODUCTION
Non-communicable disease (NCD)-related mortality and
morbidity are increasing worldwide. In 2016, an estimated
41 million people died from NCDs globally, accounting
for about 71% of global deaths. NCDs are also the leading
cause of premature death worldwide, and by far, the
greatest proportion of these premature deaths (85%)
occurs in low and middle-income countries (LMICs).1 2
The recent Global Burden of Disease report highlights
the increasing burden due to disability from NCDs.3 In
2019, diabetes is now included as a leading cause of global
disability-adjusted life years (DALYs), while 6 of the top
10 leading causes of DALYs are now due to NCDs.3 This is
a dramatic increase from 1990 when only 3 of the top 10
causes of DALYs were attributable to NCDs. This trend is
likely to continue given that the population is ageing, and
NCDs occur more commonly with advancing age.
The United Nation’s Sustainable Development Goals
(SDGs), drawn up in 2015, highlighted this growing
global burden due to NCDs and specifically set a target
to reduce by one-third premature deaths from NCDs by
2030.4 5 In 2011, global leaders met at the first UN High-
Level Meeting and acknowledged the global threat due to
NCDs.6 7 In the third UN High-Level Meeting on NCDs in
2018, this need was reiterated, but it was also recognised
that several LMICs faced system-
level challenges to
achieve their NCD goals such as poor system capacity,
weak primary healthcare, limited health infrastructure
and investments, resource constraints not limited to
financial and also health workforce related, and medical
supply-related issues.2 8–10 Despite this heightened recognition, public health experts and policymakers continue
to grapple with these constraints and challenges, which
necessitate country-
specific strategies to accelerate the
reach of evidence-based interventions (EBIs) targeting
prevention, treatment and management of NCDs, particularly in low-resource settings.9–11
Identification of the issues, challenges and enablers in
the implementation of EBIs for prevention and treatment
of NCDs, particularly in LMICs, is crucial for enhancing
scale-up efforts, and supporting countries to achieve their
SDG targets for controlling NCDs.12–14

RESEARCH GAP
World Health Organization (WHO) defines a health
system as—‘consists of organisations, people and actions
2

whose primary intent is to promote, restore or maintain health’.15 These large systems involve subsystems of
interactive elements also referred to as ‘building blocks’,
which include service delivery, infrastructure, workforce,
information, medical supplies and finance.15 16 The interactions and relationships between these system elements
and actors—the people who represent each of these
elements as stakeholders—form a continuously evolving
and dynamic system. These health system components
alongside contextual factors such as socioeconomic, political and institutional contexts form a complex environment for scale up. This complex web of interactions can
impact all stages of planning, implementation, integration, scale up and sustainability of NCD interventions but
have not been adequately researched.13 16–21 While there is
some literature available on small-scale trials of successful
implementation of interventions for NCD prevention,
information about the challenges in the large-scale implementation of such interventions and the interacting with
the health system dynamics is scarce, especially across
different contexts.14 22 23
A system wide understanding of the issues involved
in NCD scale-up efforts and the context in which the
programmes are being implemented is timely and
necessary in order to make a significant improvement
in prevention and treatment efforts globally. We define
systems thinking as ‘a holistic approach to analyse the
interrelationship between constituent parts of scale-up
interventions and the context in which the interventions
are implemented’.16–18 21 24 Systems thinking will allow
us to explore interconnectedness (context and connections), perspectives and boundaries (scope and scale)
of interventions.18 It will increase our knowledge of the
components, actors and stakeholders involved, the role
of contextual factors, processes, challenges, enablers
and pathways, and on how dynamics and relationships
between the different elements evolve as a response to the
scale up of interventions.16 17 Such information will assist
researchers, programme implementers, policymakers
and other stakeholders to plan, design, guide, implement
and evaluate the scale up of NCD interventions more efficiently and effectively.12 17
Study context: GACD 2019 scale-up call
The Global Alliance for Chronic Diseases (GACD) is an
alliance of health research funders, which co-ordinates
and supports implementation research activities that
address the prevention and treatment of the major NCDs,
such as hypertension, diabetes, cardiovascular disease,
lung disease, mental health and cancer. The GACD aims
to tackle this increasing burden of NCDs by investing
in projects that involve collaborations and partnerships
across countries and using these projects to build scientific knowledge in the area of implementation science
and research.
In 2019, the GACD released its fifth joint call inviting
proposals from projects that were ‘Scaling-up projects in
prevention and control of Hypertension and Diabetes’.
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This is the first time that global funding has been made
available for scale up of NCD-related interventions, especially in LMICs. This call has resulted in funding of 27
projects globally representing a total funding investment of approximately US$50 million.25 26 Most projects
are being implemented in LMICs spread across South
America, Africa and Asia with research partnerships and
collaborations in high-income countries (HICs) such as
Australia, USA, UK, Canada, Belgium, The Netherlands,
Slovenia and Germany. Others are targeted at disadvantaged populations in HICs. This presents a unique opportunity to follow the journey of up to 27 different projects
being scaled up in different regions, using various interventions and adopting diverse approaches, but all targeted
at preventing or treating hypertension and diabetes.
It should be acknowledged that there is no single agreed
on definition for ‘scaling up’ or ‘scale-up’, terms that
have been widely used in the fields of infectious disease
prevention and control, HIV/AIDS and maternal and
child health for many years. The WHO and ExpandNet
define scale-
up as ‘deliberate efforts to increase the
impact of successfully tested health innovations so as to
benefit more people and to foster policy and programme
development on a lasting basis’.27 Depending on the
pathway adopted, scale-up projects may be described as
being horizontal when the project expands the reach of
the programme to cover more people; vertical mostly
refers to institutionalisation and integration into policy
or health system changes; and diversification refers to
adding more interventions to the same population.23 27–31
Projects could also adopt a combination of these pathways. Scale out is another term that is encountered in
implementation science literature and mostly refers to
the adaptation efforts and strategies that are involved
while implementing EBIs to new populations or a new
delivery system, but under conditions that are mostly
similar to where the intervention was originally tested.32
AIM
The overall aim of this study is to understand the enablers
of, and challenges to, scaling up NCD-related interventions in LMICs and vulnerable groups in HICs. We will
apply systems thinking to examine up to 27 projects to
achieve the following objectives:
1. To identify which NCD interventions and activities are
currently part of scale-up research projects.
2. To understand how NCD-related scale-up projects are
planned and implemented with a focus on capturing
similarities and differences, in the enablers and challenges, that exist both within and between-countries
and contexts.
3. To identify the processes and nuances of stakeholder
engagement in the planning and development of multicountry and multisectoral collaborative scale-up projects. Specific questions include:
– How are the stakeholders identified, and roles defined?

What are the methods used to establish and sustain
engagement?
– What are the perceptions of stakeholders regarding
the planning and roll-out of interventions?
– What are the governance systems in place to manage and maintain relationships between the stakeholder groups?
– What is the relationship of the researchers with the
other stakeholders?
4. To identify how scale-up projects respond and evolve
in response to implementation challenges in the field,
such as the COVID-19 pandemic.
–

CONCEPTUAL FRAMEWORK
We will use the Consolidated Framework for Implementation Research (CFIR) to systematically collect details
of the characteristics of the intervention, the implementing organisation, the context, characteristics of the
individuals and details of the implementation process.33
The CFIR framework will also be used to guide the data
analysis and present the findings from the different case
studies. We will further use the Exploration, Preparation,
Implementation, and Sustainment (EPIS) Framework as
the overarching framework to guide analysis and present
overall findings across all the different projects.34 35 The
EPIS framework is widely used in the implementation
science literature and its main components are the four
main implementation phases forming the acronym EPIS.
It enables systematic collection of factors that bridge the
inner and outer context and point to interconnections
and interlinkages that characterise the dynamics at play
between inner and outer contexts. This framework is
well suited to apply to dynamic complex systems, such
as scale-up systems, as it considers adaptation as being a
necessary part of the implementation process to improve
fit between outer and inner contexts and is particularly
relevant in multistakeholder projects. In addition, we
will consider using other techniques to present specific
findings such as the ‘most significant change’ technique.
This technique will be used to determine the process
and causal mechanisms of changes made, and in what
situations and contexts these changes occur, using short
stories or vignettes.36 37

METHODS
Since this study is a collaborative effort of several scale-up
projects, a logic framework has been developed to help
plan and guide all aspects of this study (figure 1).38 39
Study design
We will use a multiple case study, longitudinal study
design to review up to 27 funded scale-
up projects.
Longitudinal study design enables us to follow projects
over a period of time and to capture data from the projects as snapshots of time. We will use mixed methods to
gather data at three time points from every project in real
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Figure 1 Logic model for the project. HICs, high-income countries; HTDM, hypertension and diabetes mellitus; LMICs, low-
income and middle-income countries; NCD, non-communicable disease. Timepoints comprise the following: planning (Tp),
initiation (T0), 1-year post-implementation (T1).

time, ie, as they are planned and being implemented in
the field (figure 2). The first time point will provide a
descriptive understanding of the studies, which will be
followed by two time points focused on gathering system
wide perspectives on the implementation process.21 Data
collected from every project at one time point will be used
to guide the data collection for subsequent time points.
The mixed method data collection offers the strength of
understanding issues from varied theoretical approaches
and thereby developing rich insights into complex
systems.19 40 41 The longitudinal study design will be suitable to capture and understand the enablers and challenges that stakeholders face as their projects are planned
and rolled out.16 17 21 28 It will also provide an opportunity
to determine how scale-up projects adapt and evolve in
response to challenges faced across different stages of the
scale-up process.
STUDY SETTING
The GACD secretariat and the Upscaling Working Group
The Upscaling Working Group was established in
2018, under the GACD research network and includes
academics and researchers, with projects funded through
various GACD calls since 2012, who are interested in
developing and contributing to the science of scale-up.
Teams from the 27 projects funded as part of the GACD
Scale-up Call have also been invited to be a part of this
working group (online supplemental appendix 1). We
will use the quarterly scale-up group meetings to engage
4

with members, invite them to collaborate in this study,
provide opportunities to shape the collaboration, keep
the group informed about the progress of this study and
jointly reflect on the findings.
Study participants
This protocol comprises up to 27 scale-up projects that
have been funded and are currently being implemented.
The lead researchers from the funded projects are the
main stakeholders for this study and we have codesigned
this protocol collaboratively with their involvement.
They will be our point of contact for project-related
data at all stages. We aim to capture project data from
a multistakeholder perspective at project initiation (T0)
and at 1-year post-implementation (T1). We will include
a sample of the following stakeholders from across these
projects:
1. Principal/lead investigator (PI), Co-PI or nominated
representative(s) from the project teams.
2. Other project investigators, project team members and
research partners.
3. Government representatives and policymakers.
4. Country leads, members of civil society and industry
partners.
5. Staff members or frontline workers or community
health workers.
6. Members of the community where scale-up is planned
or end-users of interventions (T1 only).
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Figure 2

Design of the study.

Patient and public involvement
Patients or the public were not involved in the design,
or conduct, or reporting, or dissemination plans of
our research. The individual projects are likely to have
community and patient involvement, depending on the
specifics of each project, and that will form a part of the
individual project protocol and is beyond the scope of
this current protocol.
Data collection
Data will be captured from each project at three different
time points using a data extraction tool and interview
guides (figure 2). The data extraction tool will map
different projects and help understand which studies
involve health policy, education (prevention) and health
systems (prevention and management). We undertook a
literature review of scale up studies, with a focus on analysis of frameworks, to develop a roadmap for conducting
scale-up studies and thereby guide development of the
study tools.27 31 42–53
Planning stage (TP)
Initially, project teams will be invited to share project
documents with information regarding how their
scale-up project in hypertension and diabetes was originally planned. These documents could include the study
protocol, funding application or any other relevant documentation that the teams are willing to share. Using our

data extraction tool (online supplemental appendix 2),
we will extract the same data from each project.
Interview at project initiation (T0)
In order to apply a systems thinking lens, semistructured
in-
depth qualitative interviews will be conducted with
a sample of up to five stakeholders from every project.
Project-related data gathered at TP will help guide the
discussions at T0, with multistakeholder interviews used
to capture individual perspectives on the challenges and
enablers to the scale-up process. We will also be able to
capture insights into the nuances of stakeholder engagement and role of relationships that exist within each
project. The interviews at this time point will also help
capture changes in the project plan that have resulted
from the COVID-19 pandemic. Four separate interview
guides, targeted specifically at principal investigators,
team members, partners, and frontline staff, have been
developed for this purpose (online supplemental appendices 3–6). The qualitative data will be audiotaped, transcribed verbatim and, if necessary, translated into English.
One-year post-initiation (T1)
Follow-up in-depth semistructured qualitative interviews
will be conducted with multiple project stakeholders for
project data at 1-year postinitiation of implementation.
Data collected at TP and T0 will help guide the discussions
at T1. Four separate follow-up interview guides have been
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developed for this purpose (online supplemental appendices 7–10). These interviews will be used to elucidate
how the projects might have been modified based on
real-life implementation challenges faced during the first
12 months of implementation. In addition to the investigators, team members, partners and frontline staff interviewed at T0, at T1, we also aim to interview members of
the community who are recipients of the intervention as
it is envisaged that all projects will have initiated engagement and consultation with this stakeholder group by this
time point. A fifth interview guide has been developed for
this purpose. (online supplemental appendix 11).
We anticipate final data collection for this study will
occur in July 2022.
Recruitment
A fair, transparent and collaborative approach will be
used to contact the lead investigators for project data. At
all stages, we will assure them of data security and confidentiality. To encourage participation, we will reiterate at
every stage that the aim of this study is to develop a better
shared understanding of scale-up of NCDs.
The project lead investigators will be our point of
contact for identifying and introducing the participants
to be interviewed for the study. All interviews will be
conducted after following ethical processes to obtain
informed consent from all participants. The potential
participants will be emailed an information sheet, with all
details of the study, and a consent form, to be signed and
returned, seeking permission for participation and audio
recording. Verbal consent will be obtained at the start of
each interview. All interviews will be conducted by the
first author (AR-C) who is a skilled qualitative researcher
with several years of experience across different countries and cultural settings. Interviews will be conducted
via phone or Zoom, according to the convenience of the
participants. All interviews will be audio recorded and
professionally transcribed for analysis purposes. We will
work in close conjunction with the teams to understand
and respect local sociocultural norms while conducting
interviews. Given the broad range of countries that
are involved in this study, language may be a challenge
while conducting some interviews. In order to minimise
bias and maintain quality of data, we will ensure that no
translation support will be taken from within the project
teams. We will, instead, identify suitable support for other
members within the broader GACD umbrella or, if necessary, employ professional translators.
Data analysis
System thinking approaches will be applied for data
collection and analysis.16 We will undertake descriptive
statistical analysis of data from TP and undertake inductive thematic coding analysis of the qualitative interviews
conducted at T0 and T1 (NVivo software, QSR International, Melbourne, Australia). Thematic analysis of qualitative data will be used to identify any similarities or
patterns in the data set from a wide range of perspectives.54
6

Initial data extraction for analysis of TP will be jointly
undertaken by the project team (AR-C, RJ, AGT) and
discussed in detail. This will provide validity of the process
and results. The extracted data will be reviewed by project
teams to ensure data accuracy. We will use descriptive
statistics and a narrative approach to summarise the
study aim, design, details of pilot studies and intervention
selection, governance, type of study and other elements
of the scaling-up process, such as range of stakeholders
involved and details related to engagement strategy
(online supplemental appendix 2), to identify patterns
and themes (objective 1).
Transcripts will be open coded using thematic analysis.
NVivo software (NVivo software V.12, QSR International,
Melbourne, Australia) will be used to assist the investigative team with organising and analysing the qualitative
data.
The draft coding scheme will be reviewed by the study
team and reconciled by consensus. AR-C will organise
participants’ responses by the corresponding codes with
support and guidance from AGT and RJ who will also
review 20% of the interviews and audit the findings. This
process will provide additional rigour, accuracy and face
validity of results.
Following coding of each study separately, inductive
thematic analysis of data obtained at T0 and T1 will help
identify any patterns of enablers and challenges within
and between countries and contexts (objective 2). This
approach will help us to explore different stakeholder
perspectives, to identify shared challenges and differences, if any, that exist across projects, and to identify
any patterns experienced by stakeholders during the scaling-up process. Inductive thematic analysis will also help
explore the process of stakeholder engagement, how
these are built and strengthened with time and determine
differences in the priorities between researchers, partners and other stakeholders (objective 3). The analysis
will explore the nature of these relationships and how the
scale-up project team govern and manage the stakeholders
for flow of information and timely decision-making.
Thematic analysis of the longitudinal collection of data
over all time points will be undertaken to assess how projects evolved or adapted in response to challenges arising
over time (objective 4). This includes an analysis of how
scale-up plans were impacted by the COVID-19 pandemic,
and how governments modified their approach to the
scale-up when faced with this global pandemic.
DISCUSSION
Programme implementers and policymakers face many
challenges in designing and delivering innovative ideas,
methods and programmes that offer effective approaches
to prevention and management of NCDs particularly
in LMICs. Governments and public health systems are
already under-resourced, so the increasing burden from
NCDs adds to the challenge of delivering programmes
in the face of other conflicting health priorities.55 For
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instance, there are reports that the COVID-
19 global
pandemic has interrupted public health services and
NCD efforts in nearly 75% of countries surveyed.56
Other challenges faced by health systems when implementing NCD-related health programmes include lack
of a national NCD policy, inadequate funding allocation,
weak health systems and preparedness, poor capacity of
health workers and frontline staff and poor technical
infrastructure.57 58
Scale-up of health system interventions is typically large
collaborative efforts and include several stakeholders
across different sectors of policymaking, public health,
research, implementation agencies, governments, civil
society and others.16 21 These different stakeholders
form a complex system with several interactive elements,
processes and actors who may at times have conflicting or
differing priorities but have to align their common interests during implementation.15–17 21 28 Presently, there is
little information and understanding of these individual
components and their interactions, particularly in relation to the scale-up of complex interventions for NCDs.
Systems thinking is an approach that can help explore
and identify the individual elements within complex
health systems.16 17 By applying systems thinking to these
GACD-funded projects, we will be able to identify how
interactions and relationships can potentially influence
the scaling-up process. This will help better design these
complex interventions in the future, including practical
strategies to encourage buy-
in and continued engagement, to better promote sustainability.
A major advantage of our analysis is the potential to
study a diversity of contexts and a diversity of NCD interventions that can individually influence scale-up efforts,
such as the public health context, NCD context, political
context, health and other policy context and sociocultural factors.44 49 This may help to identify commonalities
that exist across regions, countries or contexts. It may
also identify some unique and powerful country-specific
and context-specific factors that influence the scale-up
process. Furthermore, it may help identify the role of
governance and the political economy around NCD
prevention and control. Together, this may further add to
better planning and implementation of scaling strategies
in under-resourced settings in the future.59 60
The design of our study, initiated prior to commencement of the projects, is uniquely placed to identify how
teams recognise, respond, adapt and modify or potentially halt and/or discard their plans to scale-
up as
they encounter challenges in the field. The COVID-19
pandemic is an example of a common challenge faced
in the early implementation phase of these scale-up projects, so it provides a means to identify this adaptation and
evolution process.
There are a number of limitations to the study. First,
many of the contributing authors of this paper are
also investigators of the projects and hence a part of
this working group. In order to minimise conflict of
interest and bias, all data collection and analysis will

be conducted by an independent team of researchers,
within the working group, who are not involved in any
of the scale-up projects. The inclusion of investigators as
members of this working group also presents a strength, in
that researchers may have the opportunity to learn from
each other, to improve the scalability of their intervention
and to increase internal validity of findings through joint
reflection. In addition, we are reliant on project teams
to introduce us to their stakeholders/partners, and this
is likely to result in some selection bias. To minimise this
bias, we obtain a list of stakeholders for each project,
and the study team then makes a final decision on who
to invite. Third, we initially aimed to capture changes
during the planning phase and early implementation
phase. But, because the first round of interviews is occurring during COVID-19, we are now unlikely to be able
to capture other real-world implementation challenges,
which would have contributed to our understanding of
scale-up science. The major threat of COVID-19, to country’s health systems, also presents an opportunity to study,
in the real world, how NCD interventions are affected by
health system challenges. Finally, we aspire to interview
the same set of stakeholders at both T0 and T1, but this
may not always be possible due to people’s commitments,
availability and staff turnover. However, fresh insights
obtained through these newer participants may add to
the overall quality of feedback received.
CONCLUSION
This collaborative effort will provide an opportunity to
systematically evaluate how processes such as stakeholder
engagement and governance evolve over time in response
to challenges and facilitators in the field, and thereby
contribute to scale-up efforts for NCDs in low-resource
settings in the future. As a practical output, this research
effort should enable us to identify a suitable framework,
or a combination of different frameworks, for use by
researchers, programme implementers and policymakers
worldwide.
ETHICS AND DISSEMINATION
Each project funded under the scale-up call will have its
own individual ethics approval, and independent of this
currently described protocol. This protocol has been independently approved by the Monash University Human
Research Ethics Committee (HREC number 23482).
This study is a collaborative study within the working
group and has no bearing whatsoever on individual project’s research, ethics or dissemination plans. This project
has been codesigned with open and transparent processes
of consultation with all members of the upscaling working
related
group. Written consent for sharing of project-
data will be obtained from lead investigators, and written
and verbal consent will be obtained prior to interviews.
Dissemination of the results, from this study, to research,
clinical and health communities will be at the annual
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GACD scientific meetings, other scientific conferences
and via international peer-reviewed journals.
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Appendix 1: List of scale-up projects funded in the GACD scale-up call in 2019
Name
1. DIABFRIL - LATAM

2. SUNI-SEA - Scaling-up NCD
Interventions in South East Asia
3. SCUBY
4. WHO PEN at Scale
5. INTE-AFRICA
6. Evaluating the role of pharmacists
and m-Health strategies in the
management of hypertension in
General Pueyrredon
7. Implementation of a model of
management of myocardial
infarction patients.
8. Healthy Schools
9. Use of mHealth and social media to
strengthen a primary prevention
program for type2 diabetes in public
primary care clinics
10. Evaluating and bringing to scale
alternative food networks to address
diabetes mellitus and hypertension
11. Scaling up the Community Health
Assessment Program in the
Philippines (CHAP-P)
12. Community mHealth Integrated Care
(ComHIC) to manage
hypertension/diabetes in Tanzania’s
overburdened health system
13. Community-based lifestyle
intervention for diabetes
management in rural Nepal
14. School-based education programme
to reduce salt: Scaling up in China
(EduSalts)
15. Scaling up the Primary Health
Integrated Care Project for Chronic
Conditions in Kenya an
implementation research project

Location of scaleup (country)
Argentina, Chile,
Columbia, Mexico,
Peru
Indonesia,
Myanmar, Vietnam
Belgium, Cambodia,
Slovenia
Eswatini
Tanzania, Uganda
Argentina

Programme
contact
Leocadio Rodriguez
Manas

Belgium

Carlos Daniel Tajer

Argentina
Argentina

Jonatan Konfino
Andrea
Beratarrechea

Ecuador

Malek Batal

Philippines

Gina Agarwal

Tanzania

Keiko Nakamura

Nepal

Tomohiko Sugishita

China

Feng He

Kenya

Pablo Perel

Maarten Postma
Josefien van Olmen
Jan-Walter De Neve
Shabbar Jaffar
Maria Eugenia
Esandi
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Appendix 1: List of scale-up projects funded in the GACD scale-up call in 2019 [20]
Name
16. The Bangladesh D:CLARE Project
[Diabetes: Community-Led
Awareness, Response and Evaluation]
17. CHArMING - Control of
Hypertension and diAbetes in MINas
Gerais
18. Scaling up food policy interventions
to reduce non-communicable diseases
in the Pacific Islands
19. An evaluation of the Resolve to Save
Lives salt reduction program in China
20. Strengthening China’s essential public
health package for hypertension and
diabetes care in rural village clinics
through meaningful use of health
information systems
21. Scale-up of a primary care
intervention for cardiovascular risk
management in Malang, Indonesia
22. Scaling up interventions to improve
the control of hypertension and
diabetes in partnership with the
governments of Kerala and Tamil
Nadu
23. Evaluating the implementation of
Group Empowerment and Training
(GREAT) for diabetes in South
Africa.
24. Assessing COPC scale-up in selected
learning sites of the Cape Town
Metro: community-based NCD
prevention interventions
(ACCELERATE)
25. Evaluating the implementation and
scale-up of Nigeria National Salt
reduction program
26. Implementing and scaling up a teambased care strategy for hypertension
control in Colombia and Jamaica.
27. Addressing hypertension and diabetes
through community engaged systems
in Puno, Peru (Andes study)

Location of scaleup (country)
Bangladesh

Programme
contact
Ed Fottrel

Brazil

James Batchelor

Fiji, Samoa

Jacqui Webster

China

Bruce Neal

China
David Peiris

Indonesia

Anushka Patel

India

Brian Oldenburg

South Africa

Robert Mash

South Africa

S Read

Nigeria

Dike Bevis Ojji

Jamaica and
Colombia

Marshall TullochReid

Peru

German Malaga
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Appendix 2: Details of elements extracted using the Data Extraction Tool
(TP)
1. Location of scale-up project, types of project documents shared by teams, key team members.
2. Identification of the need or gap that exists in the population currently.
3. An understanding of the scale-up project:
a. Project aim or goal.
b. Type of scale-up project - Policy related /Service improvement / anything else
c. Smallest Administrative Unit where the scale-up is planned.
d. Has any framework been used to support whole project?
e. What is the objective of the project? (actions taken to achieve the aims).
f. Details about Study Design, Phases/ Key steps/ Components of the project.
4. Details about the intervention being scaled-up.
5. Details about what is novel or innovative about the intervention.
6. Primary outcomes and outcome measures.
7. Secondary outcomes and outcome measures.
8. Expected project outputs.
9. Understanding of the stakeholders and project team involved in the scale-up:
a. Who are the beneficiaries / frontline staff/ other beneficiaries?
b. Is there a Partnering organisation / Industry partner / NGO involved?
c. Other professional bodies or stakeholders involved.
d. Who are the government stakeholders?
e. Any specific details of engagement strategy with stakeholders.
10. Details about the pilot stage:
a. whether a pilot was conducted prior or if it is being conducted as a part of scale-up.
b. Details about pilot timing, external funding, whether it was / will be evaluated.
11. Specific information about the scale-up:
a. Goal
b. details of specific framework, if used, to guide scale-up
c. whether it is horizontal or vertical scale-up.
d. whether there is phase to test the scale-up.
12. Understanding of the national context for scale-up and whether there is a national policy in place
for managing NCDs and any other response by the government national or local to NCD
management.
13. Is cost-effectiveness and process evaluation analysis being conducted?
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Appendix 3: Timepoint 0 (T0)- Baseline Interview guide for Principal
Investigators (or representative identified by them)
_________________________________________________________________________________
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect baseline information about your scale up study
__________________________________________________________________________________
1. Can you tell me a little bit about yourself and your motivations that led to this scale-up project
2. Please tell me a little about the scale-up project?
a. Can you explain briefly what is being scaled-up?
b. What was the opportunity to scale up? Why?
c. Is there anything new or novel about what is being scaled-up?
i. If it is new, what is new about it (e.g. a technical innovation/process (new
delivery approach), organizational innovation (new partnerships), or a
combination)?
d. What was the architecture for this scaling opportunity?
e. Who were the actors and players?
f. As a PI do you think the scale-up is a fairly simple model or is it complex? Why?
g. Is the scale-up a horizontal or vertical scale-up?
h. Is the scale up model selected based on what actually will happen if
government/health system will take over? If not, how might it change?
i. Are there any risks, fears or weaknesses?
3. Please tell me a little bit about the partnering organisation?
• What is its role?
• In your opinion what are the main strengths that the organisation brings?
• What are the challenges that you think the organisation will face during the scale-up
process?
4. Could you tell me a little bit about the Chief Investigator/s?
a. What expertise do they bring?
b. How well do you know them? Have you worked with them previously?
c. Does it make a difference if you know them well or not? Why?
d. How do you, the Chief Investigators & other key partnering organisation members plan
to keep in touch during the process?
5. Who you think are the relevant stakeholders and end-beneficiaries in your project?
a. Have you started consulting with them?
i. If so, how?
ii. If not, at what stage will you be consulting with them?
b. What is their role? What are the challenges in ensuring their buy-in?
6. Could you tell me a little bit about the governance structure of the project team and
collaborators?
a. How is the project structured to enable input from all stakeholders?
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b. How do you meet (e.g. Zoom, face-to-face) and how often?
c. How are decisions made and who makes the final decision regarding project processes?
7. What do you think about the health system in the countries where the project is being
implemented? Alternative questions for those who have projects that do not involve the health
system: What do you think about the health system and other relevant system in the countries
where the project is being implemented?”
a. Is it generally open to change and receptive and encouraging to new ideas?
b. What are the critical challenges that the health system poses with regard to
implementation/adoption/scale up of the project? How do you know this?
c. How does the project design take into account the health system challenges? If you
project is across several LMIC countries how does the design reflect the changing local
system?
d. We noted in the proposal that you have included process and economic evaluations.
Could you comment how you think the findings from these evaluations may address the
health system challenges and inform the end-users?
8. Are there any industry stakeholders for this project (specific probe if not mentioned in 7 above, or
for expansion)?
a. Who are they?
b. What is their role? What are the challenges in ensuring their buy-in?
c. At what stage will you be consulting with them?
9. Please tell me a little about the local government and key government stakeholders (specific
probe for expansion).
a. What is their role and how important is their role?
b. What do you think are the challenges in partnering with them?
c. How do you plan to ensure their buy-in and what stage of the project is this important?
d. Do you see any ongoing issues with regard to this?
10. Are there any other health service providers who are involved in the delivery of the program, in
the technical advisory board, designing the intervention, or otherwise involved in this project
(specific probe if not mentioned in 7 above, or for expansion)?
a. What is their role?
b. How do you plan encourage them to participate and contribute?
c. What are the challenges in keeping them motivated and interested?
11. Tell me a little about the end-beneficiaries of this program
a. What are their health needs currently with regard to hypertension and diabetes?
b. How are these needs being met currently?
c. At what stage of the program implementation are they being consulted and in what
manner?
d. Why do you think they will adopt and continue with the model/innovation?
e. Has the same group of beneficiaries successfully taken up any program previously? Is
there a history of acceptance?
f. What do you perceive to be the main challenges in their uptake of the program?
g. How do you plan to deal with these challenges?
12. Tell me a little bit about the front-line staff who will be delivering the program?
a. How important do you think their role is?
b. At what stage of the program is their role most important?
c. Do they have other conflicting projects or programs that they work in?
d. What are their challenges and motivators to promote this programme?
e. What is the incentive for them to promote this program?
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f.

What sort of resources are being invested in their training? Is there written documentation
of all policies that they need to follow?
g. Has any training material been prepared for their work?
13. Has a pilot been conducted? If yes:
a. When was the pilot conducted? Where was it conducted?
b. Was it in the same location as the scale up? (same local environment or different?)
c. Was the pilot evaluated? If so, what documentation and methods were used to gather
data?
d. How did you or the team assess that the pilot program could be scaled up? How do you
know that the program is effective (that it works)? How do you know that the program is
an efficient way of delivering to the community?
e. What were some of the challenges that the team faced during pilot stage? How did you
deal with them?
f. What were the main learnings from the pilot? Do you think that the pilot provided any
tweaking to the original program strategy?
g. What were the learnings about stakeholders- motivators, buy-in, challenges/ barriers?
h. What were the challenges that arose from the health system perspective?
i. Has the intervention changed because of the results of the pilot?
j. How are you measuring fidelity?
k. Did you undertake a cost-effectiveness of the pilot intervention? If yes, how did you use
that information for scale up? If not done at pilot, then why not?
If no pilot was conducted:
a. Could you please explain why a pilot or feasibility study was not conducted?
b. How does the team plan to scope the study, identify local challenges and barriers, and
determine what works well and what does not work well?
14. Please tell me a little bit about the scale-up plan and strategy
a. Is there a specific plan or strategy that is going to be used to guide the process? Has it
been documented?
b. Which members of the team, partners and other stakeholders are aware of this strategy?
c. Which members of the team, partners and other stakeholders have been consulted while
drawing this up?
d. Have you used any framework to guide the scale up design and strategy? Why did you
apply that particular framework? Did you consider any others?
e. Do you see any potential issues for long term sustainability of the program?
f.

What do you think will happen if a new unplanned challenge emerges during
implementation? What qualities do you think your team or organisation has to cope with
this? How will the team know and respond?

g. Are you measuring cost-effectiveness of scale up? If so could you briefly explain how?
If not, why not?
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Appendix 4: Timepoint 0 (T0)- Baseline Interview guide for Chief
Investigators and Project Team Members
_________________________________________________________________________________
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect baseline information about the scale up project
__________________________________________________________________________________
1. Can you tell me a little bit about yourself and your motivations that led to this scale-up
project
2. Please tell me a little about the scale-up project?
j. Can you explain briefly what is being scaled-up?
k. What was the opportunity to scale up? Why?
l. Is there anything new or novel about what is being scaled-up?
i. If it is new, what is new about it (e.g. a technical innovation/process (new
delivery approach), organizational innovation (new partnerships), or a
combination)?
m. What was the architecture for this scaling opportunity?
n. Who were the actors and players?
o. As a CI do you think the scale-up is a fairly simple model or is it complex? Why?
p. Is the scale-up a horizontal or vertical scale-up?
q. Are there any risks, fears or weaknesses?
3. Could you tell me a little bit about the Principal Investigator/s?
e. What expertise do they bring?
f. How well do you know them? Have you worked with them previously?
g. Does it make a difference if you know them well or not? Why?
h. How do you plan to keep in touch during the process?
4. Who you think are the relevant stakeholders and end-beneficiaries in your project?
a. Have you started consulting with them?
i. If so, how?
ii. If not, at what stage will you be consulting with them?
b. What is their role? What are the challenges in ensuring their buy-in?
5. Could you tell me a little bit about the governance structure of the project team and
collaborators?
d. How is the project structured to enable input from all stakeholders?
e. How do you meet (e.g. Zoom, face-to-face) and how often?
f. How are decisions made and who makes the final decision regarding project processes?
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6. What do you think about the health system in the countries where the project is being
implemented? Alternative questions for those who have projects that do not involve the health
system: What do you think about the health system and other relevant system in the countries
where the project is being implemented?”
a. Is it generally open to change and receptive and encouraging to new ideas?
b. What are they critical challenges that the health system (other system) poses with
regard to the project? How do you know this?
c. How does the project design take into account the health (or other) system
challenges?
7. Are there any industry stakeholders for this project (specific probe if not mentioned in 7
above, or for expansion)?
a. Who are they?
b. What is their role? What are the challenges in ensuring their buy-in?
c. At what stage will you be consulting with them?
8. Please tell me a little about the local government and key government stakeholders (specific
probe for expansion).
a. What is their role and how important is their role?
b. What do you think are the challenges in partnering with them?
c. How do you plan to ensure their buy-in and what stage of the project is this
important?
d. Do you see any ongoing issues with regard to this?
9. Are there any other health service providers who are involved in the delivery of the program
(specific probe if not mentioned in 7 above, or for expansion)?
a. What is their role?
b. How do you plan encourage them to participate and contribute?
c. What are the challenges in keeping them motivated and interested?
10. Tell me a little about the end-beneficiaries of this program
a. What are their health needs currently with regard to hypertension and diabetes?
b. How are these needs being met currently?
c. At what stage of the program implementation are they being consulted and in what
manner?
d. Why do you think they will adopt and continue with the model/innovation?
e. Has the same group of beneficiaries successfully taken up any program previously? Is
there a history of acceptance?
f. What do you perceive to be the main challenges in their uptake of the program?
g. How do you plan to deal with these challenges?
11. Tell me a little bit about the front-line staff who will be delivering the program?
a. How important do you think their role is?
b. At what stage of the program is their role most important?
c. Do they have other conflicting projects or programs that they work in?
d. What are their challenges and motivators to promote this programme?
e. What is the incentive for them to promote this program?
f. What sort of resources are being invested in their training? Is there written
documentation of all policies that they need to follow?
g. Has any training material been prepared for their work?
12. Has a pilot been conducted? If yes:
a. When was the pilot conducted? Where was it conducted?
b. Was it in the same location as the scale up? (same local environment or different?)
c. Was the pilot evaluated? If so, what documentation and methods were used to gather
data?
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d. How did you or the team assess that the pilot program could be scaled up? How do
you know that the program is effective (that it works)? How do you know that the
program is an efficient way of delivering to the community?
e. What were some of the challenges that the team faced during pilot stage? How did
you deal with them?
f. What were the main learnings from the pilot? Do you think that the pilot provided
any tweaking to the original program strategy?
g. What were the learnings about stakeholders- motivators, buy-in, challenges/ barriers?
h. What were the challenges that arose from the health system perspective?
i. Has the intervention changed because of the results of the pilot?
j. How are you measuring fidelity?
If no pilot was conducted:
c. Could you please explain why a pilot or feasibility study was not conducted?
d. How does the team plan to scope the study, identify local challenges and barriers, and
determine what works well and what does not work well?
13. Please tell me a little bit about the scale-up plan and strategy
h. Is there a specific plan or strategy that is going to be used to guide the process? Has it
been documented?
i. Which members of the team, partners and other stakeholders are aware of this strategy?
j. Which members of the team, partners and other stakeholders have been consulted while
drawing this up?
k. Do you see any potential issues for long term sustainability of the program?
l.

What do you think will happen if a new unplanned challenge emerges during
implementation? What qualities do you think your team or organisation has to cope with
this? How will the team know and respond?

m. Are you measuring cost-effectiveness? If so could you briefly explain how?
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Appendix 5: Timepoint 0 (T0)- Baseline Interview guide for local
government stakeholders
________________________________________________________________________________
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect baseline information about your scale up project.
__________________________________________________________________________________
1. Can you tell me a little bit about yourself and your motivations that made you to partner in
this scale-up project
2. Please tell me a little about the scale-up project?
r. Can you explain briefly what is being scaled-up?
s. What was the opportunity to scale up? Why?
t. Is there anything new or novel about what is being scaled-up?
i. If it is new, what is new about it (e.g. a technical innovation/process (new
delivery approach), organizational innovation (new partnerships), or a
combination)?
u. What was the architecture for this scaling opportunity?
v. Who were the actors and players?
w. As a government representative do you think the scale-up is a fairly simple model or
is it complex? Why?
x. Are there any risks, fears or weaknesses?
3.
•
•
•
•

Please tell me a little bit about your government’s role in this project?
Why does this project interest your local government?
What is your governments role in this project?
In your opinion what are the main strengths that your local government brings?
What are the challenges that you think the government systems will face during the scale-up
process?

4. Could you tell me a little bit about the local organisation in the scale-up?
i. What expertise do they bring?
j. How well do you know them? Have you worked with them previously?
k. Does it make a difference if you know them well or not? Why?
l. How do you, plan to keep with the team during the process? What challenges do you see
in keeping this relationship through the process?
5. When were you first informed about this project? What were you told? Who introduced this
project to you?
6. Could you tell me a little bit about the governance structure of the project team and
collaborators?
g. How is the project structured to enable input from all stakeholders?
h. How do you meet (e.g. Zoom, face-to-face) and how often?
i. How are decisions made and who makes the final decision regarding project processes?
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7. What do you think about the health system in your country?
a. Is it generally open to change and receptive and encouraging to new ideas?
b. What are they critical challenges that the health system poses with regard to the
project? How do you know this?
c. How does the project take into account the health system challenges?
8. Tell me a little about the end-beneficiaries of this program
a. What are their health needs currently with regard to hypertension and diabetes?
b. How are these needs being met currently?
c. At what stage of the program implementation are they being consulted and in what
manner?
d. Why do you think they will adopt and continue with the model/innovation?
e. Has the same group of beneficiaries successfully taken up any program previously? Is
there a history of acceptance?
f. What do you perceive to be the main challenges in their uptake of the program?
g. How do you plan to deal with these challenges?
9. Were you involved in a pilot of this project? If yes:
a. How did you assess that the pilot program could be scaled up? How do you know that
the program is effective (that it works)? How do you know that the program is an
efficient way of delivering to the community?
b. What were some of the challenges that your local government faced during pilot
stage? How did you deal with them?
c. What were the main learnings from the pilot? Do you think that the pilot provided
any tweaking to the original program strategy?
d. What were the challenges that arose from the health system perspective?
e. Has the intervention changed because of the results of the pilot?
10. Please tell me a little bit about the scale-up plan and strategy
n. Is there a specific plan or strategy that is going to be used to guide the process? Has it
been documented?
o. Were you consulted in this process?
p. Do you see any potential issues for long term sustainability of the program?
q. What do you think will happen if a new unplanned challenge emerges during
implementation? What qualities do you think your local government has to cope with
this?
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Appendix 6: Timepoint 0 (T0) Baseline Interview front-line workers and
staff
_________________________________________________________________________________
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
__________________________________________________________________________________
1. Tell me little bit about the community and end-beneficiaries of this project:
a. What is their general awareness level about hypertension and diabetes?
b. What are their health needs currently with regard to hypertension and diabetes?
c. How are these needs being met currently?
d. Were they involved during or are they being consulted and in what manner?
e. Why do you think they will adopt and continue with the model/innovation?
f. Has the same group of beneficiaries successfully taken up any program previously? Is
there a history of acceptance?
g. What do you perceive to be the main challenges in their uptake of the program?
2. Tell me about your role and work on this project?
a. Who is your employer?
b. What are your main responsibilities?
c. When did you start working in this role?
d. Why did you take up this job?
e. What do you think will help you to do this role well?
f. What do you think is the most challenging or difficult thing about your role?
3. Do you have any other similar projects or programs that you work for presently?
a. Are these roles similar or different? In what way?
b. Do you think this be a challenge for you to balance all these roles?
4. About governance systems:
a. Who do you report to and how do you report to them?
b. What supports do you receive from the organisation?
c. If you have a problem with regard to this project- what will you do? Who will you
contact?
5. Do you think Covid-19 might have an impact on your job in anyway?
a. How?
b. Did you have to change your working in any manner?
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Appendix 7: Timepoint 1 (T1) Follow-up Interview guide for Principal
Investigators (or representative identified by them)
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect baseline information about your scale up study
__________________________________________________________________________________
1. Last time you told us about the scale-up project, and now I’d like to know how this might have
changed?
a. Has the scale-up unit changed? If so, how?
b. Has the opportunity for scale up changed? If so how?
c. Has the novelty about what is being scaled-up changed?
i. If so, how?
d. Has the architecture for this scaling opportunity changed? How?
e. Have the actors and players changed? How?
f. Last time you stated that the scale-up was a fairly simple/complex model? Has your
view changed? How?
g. Has there been a change to how the government/health system will take over the
scale-up project? How?
h. Have any new risks, fears or weaknesses arisen?
2. Last time you told me a little bit about the partnering organisation ...
a. Has their role changed?
b. Last time you stated that their main strength were ..... Has your view of this changed?
How?
c. What have been the challenges that you think the organisation has faced during the
scale-up process?
3. Last time you told us a little bit about the Chief Investigator/s, and I’d like to know how your
perceptions have changed?
a. The expertise that they bring.
b. How well you know them?
c. How have you kept in touch during the process?
4. Last time you stated that the relevant stakeholders and end-beneficiaries in your project were
....
a. Have you started consulting with them?
i. If so, when did you start consulting with them? How?
ii. If not, at what stage will you be consulting with them?
b. Has their role changed since the last time we spoke? What have been the challenges
in ensuring their buy-in?
5. Last time you told me about the governance structure of the project team and collaborators.
You stated that it was .......
a. Has this structure changed? If not how has it enabled input from all stakeholders? If
so, how has it changed and how has it facilitated input from all stakeholders?
b. How have you met and how often? Has it been enough?
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c. How have the decisions been made and who makes the final decision regarding
project processes?
6. Last time you told me that the health system in the countries where the project is being
implemented were.... Alternative questions for those who have projects that do not involve the
health system: Last time you told me that the health system and other relevant system in the
countries where the project is being implemented were....
a. Has your view changed about whether it is generally open to change and receptive
and encouraging to new ideas? On what do you base this view?
b. What are they critical challenges that the health system has posed with regard to the
project? How do you know this?
c. How have you been able to take into account the health system challenges
d. If relevant: How has the process and economic evaluations helped to address the
health system challenges and inform the end-users?
7. Last time you told me about the specific needs of the health beneficiaries. You stated that ....
a. Has your view changed about their health needs with regard to hypertension and
diabetes?
b. At what stage of the program implementation have they been consulted and in what
manner?
c. Do you think they have adopted the model/innovation? Will they continue with it?
d. What do you perceive have been their main challenges in their uptake of the
program?
e. How have you dealt with these challenges?
8. Last time you told me a little bit about the front-line staff who will be delivering the program.
In retrospect ....
a. How important do you think their role is?
b. At what stage of the program has their role been most important?
c. Have they had other conflicting projects or programs that they work in?
d. What do you think have been their challenges and motivators to promote this
programme?
e. What has been their incentive to promote this program?
f. What sort of resources are were invested in their training? Has this changed over the
course of the study? Was there written documentation of all policies that they need to
follow and has this changed?
g. Has their training material changed? If so, how?
9. Last time you told as that a pilot was being conducted as part of this project (if applicable):
a. When was the pilot conducted? Where was it conducted?
b. Was it in the same location as the scale up? (same local environment or different?)
c. Was the pilot evaluated? If so, what documentation and methods were used to gather
data?
d. How did you or the team assess that the pilot program could be scaled up? How do
you know that the program is effective (that it works)? How do you know that the
program is an efficient way of delivering to the community?
e. What were some of the challenges that the team faced during pilot stage? How did
you deal with them?
f. What were the main learnings from the pilot? Do you think that the pilot provided
any tweaking to the original program strategy?
g. What were the learnings about stakeholders- motivators, buy-in, challenges/ barriers?
h. What were the challenges that arose from the health system perspective?
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Has the intervention changed because of the results of the pilot?
How are you measuring fidelity?

10. Please tell me a little bit about the scale-up strategy
a. Has there been a specific plan or strategy that has been used to guide the process?
Has it been documented?
b. Which members of the team, partners and other stakeholders are aware of this
strategy?
c. Which members of the team, partners and other stakeholders have been consulted
while drawing this up?
d. Do you see any potential issues for long term sustainability of the program?
e. Has a new unplanned challenge emerged during implementation? How has your team
or organisation coped with this? How did the team know and how did they respond?
f.

Have you been measuring cost-effectiveness? If so could you briefly explain how?
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Appendix 8: Timepoint 1 (T1) - Follow-up Interview guide for Chief
Investigators and Project Team members
_________________________________________________________________________________
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect information about the scale up project
__________________________________________________________________________________
1. Last time you told us about the scale-up project, and now I’d like to know how this might have
changed?
a. Has the scale-up unit changed? If so, how?
b. Has the opportunity for scale up changed? If so how?
c. Has the novelty about what is being scaled-up changed?
i. If so, how?
d. Has the architecture for this scaling opportunity changed? How?
e. Have the actors and players changed? How?
f. Last time you stated that the scale-up was a fairly simple/complex model? Has your
view changed? How?
g. Has there been a change to how the government/health system will take over the
scale-up project? How?
h. Have any new risks, fears or weaknesses arisen?
2. Last time you told us a little bit about the Principal Investigator/s, and I’d like to know how
your perceptions have changed?
a. The expertise that they bring.
b. How well you know them?
c. How have you kept in touch during the process?
3. Last time you stated that the relevant stakeholders and end-beneficiaries in your project were
....
a. Have you started consulting with them?
i. If so, when did you start consulting with them? How?
ii. If not, at what stage will you be consulting with them?
b. Has their role changed since the last time we spoke? What have been the challenges
in ensuring their buy-in?
4. Last time you told me about the governance structure of the project team and collaborators.
You stated that it was .......
a. Has this structure changed? If not how has it enabled input from all stakeholders? If so,
how has it changed and how has it facilitated input from all stakeholders?
b. How have you met and how often? Has it been enough?
c. How have the decisions been made and who makes the final decision regarding project
processes?
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5. Last time you told me that the health system in the countries where the project is being
implemented were ....
a. Has your view changed about whether it is generally open to change and receptive
and encouraging to new ideas? On what do you base this view?
b. What are they critical challenges that the health system has posed with regard to the
project? How do you know this?
c. How have you been able to take into account the health system challenges
6. Last time you told me about the specific needs of the health beneficiaries. You stated that ....
a. Has your view changed about their health needs with regard to hypertension and
diabetes?
b. At what stage of the program implementation have they been consulted and in what
manner?
c. Do you think they have adopted the model/innovation? Will they continue with it?
d. What do you perceive have been their main challenges in their uptake of the
program?
e. How have you dealt with these challenges?
7. Last time you told me a little bit about the front-line staff who will be delivering the program.
In retrospect ....
a. How important do you think their role is?
b. At what stage of the program has their role been most important?
c. Have they had other conflicting projects or programs that they work in?
d. What do you think have been their challenges and motivators to promote this
programme?
e. What has been their incentive to promote this program?
f. What sort of resources are were invested in their training? Has this changed over the
course of the study? Was there written documentation of all policies that they need to
follow and has this changed?
g. Has their training material changed? If so, how?
8. Last time you told as that a pilot was being conducted as part of this project (if applicable):
a. When was the pilot conducted? Where was it conducted?
b. Was it in the same location as the scale up? (same local environment or different?)
c. Was the pilot evaluated? If so, what documentation and methods were used to gather
data?
d. How did you or the team assess that the pilot program could be scaled up? How do
you know that the program is effective (that it works)? How do you know that the
program is an efficient way of delivering to the community?
e. What were some of the challenges that the team faced during pilot stage? How did
you deal with them?
f. What were the main learnings from the pilot? Do you think that the pilot provided
any tweaking to the original program strategy?
g. What were the learnings about stakeholders- motivators, buy-in, challenges/ barriers?
h. What were the challenges that arose from the health system perspective?
i. Has the intervention changed because of the results of the pilot?
j. How are you measuring fidelity?
9. Please tell me a little bit about the scale-up strategy
a. Has there been a specific plan or strategy that has been used to guide the process? Has it been
documented?
b. Which members of the team, partners and other stakeholders are aware of this strategy?
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c. Which members of the team, partners and other stakeholders have been consulted while
drawing this up?
d. Do you see any potential issues for long term sustainability of the program?
e. Has a new unplanned challenge emerged during implementation? How has your team or
organisation coped with this? How did the team know and how did they respond?
f.

Have you been measuring cost-effectiveness? If so could you briefly explain how?
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Appendix 9: Timepoint 1 (T1) Follow-up Interview guide for Government
stakeholders
_________________________________________________________________________________
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect follow up information about your scale up project.
__________________________________________________________________________________
1. Last time you told us about the scale-up project, and now I’d like to know how this might have
changed?
a. Has the scale-up unit changed? If so, how?
b. Has the opportunity for scale up changed? If so how?
c. Has the novelty about what is being scaled-up changed?
i. If so, how?
d. Has the architecture for this scaling opportunity changed? How?
e. Have the actors and players changed? How?
f. Last time you stated that the scale-up was a fairly simple/complex model? Has your view
changed? How?
g. Have any new risks, fears or weaknesses arisen?
2. Last time you told me a little bit about your government’s role in this project ...
a. Has there been a change in the interest of your local government to this project? How?
b. Has your government’s role in this project changed?
c. Last time you told me that the main strengths that your local government brings were ....
Has your view of this changed? How?
d. What have been the challenges that you think the government has faced during the scaleup process?
3. Last time you told me a little bit about the local organisation and their role in the scale-up
process? Have your perceptions changed about ...
a. The expertise that they bring.
b. How well you know them?
c. How have you kept in touch during the process?
d. Have they actively kept in touch with you? What have been the challenges in providing
the government’s perspective?
4. Last time you told me about the governance structure of the project team and collaborators. You
stated that it was .......
a. Has this structure changed? If not how has it enabled input from all stakeholders? If so,
how has it changed and how has it facilitated input from all stakeholders?
b. How have you met and how often? Has it been enough?
c. How have the decisions been made and who makes the final decision regarding project
processes?
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5. Last time you told me that the health system in your country was ...?
a. Has your view changed about whether it is generally open to change and receptive and
encouraging to new ideas? On what do you base this view?
b. What are they critical challenges that the health system has posed with regard to the
project? How do you know this?
c. How have you been able to take into account the health system challenges
d. If relevant: How has the process and economic evaluations helped to address the health
system challenges and inform the end-users?
6. Last time you told me about the specific needs of the health beneficiaries. You stated that ....
a. Has your view changed about their health needs with regard to hypertension and
diabetes?
b. At what stage of the program implementation have they been consulted and in what
manner?
c. Do you think they have adopted the model/innovation? Will they continue with it?
d. What do you perceive have been their main challenges in their uptake of the program?
e. How have you dealt with these challenges?
7. Please tell me a little bit about the scale-up strategy
a. Has there been a specific plan or strategy that has been used to guide the process? Has it
been documented?
b. Have you been consulted in this process?
c. Do you see any potential issues for long term sustainability of the program?
d. Has a new unplanned challenge emerged during implementation? How has your local
governmentcoped with this? How did you become aware of this and how did you
respond?
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Appendix 10: Timepoint 1 (T1) Follow-up interview guide for front-line
workers and staff
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
1. Can you share some of your experiences, working on this role, over the past year?
a. What have you enjoyed about your role?
b. What has been the highlight for you?
2. What has been the most challenging thing for you, in this role, in the last 1 year?
a. Has there been any challenges with the community or end-beneficiaries? What?
b. Has there been any challenges from the organisation? What?
c. Has there been any challenges from government? What?
d. Did you only you feel it or did other staff also face a similar situation?
e. How did you and other staff cope with it?
f. Was the problem resolved? How?
g. Who came up with the solution?
3. Last time you told me about the governance systems to help communicate with the organisationdo you think that has worked well in the last year? Have you had any problems with this?
4. Is there anything else that you would like to share with me about what worked well and didn’t
work well for you over the last year in this role?
****Thank you for your participation *****
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Appendix 11: Timepoint 1 (T1) Interview guide for community members
where scale up is planned or end users of the intervention
Thank you for agreeing to take part in this interview. My name is Anusha and I am undertaking this
interview as a part of my PhD Research the title of which is “Applying a systems lens to identify
challenges, enablers and barriers to the GACD scale up interventions”. My supervisors for the PhD
research are Prof. Amanda Thrift from Monash University and A/Prof Rohina Joshi from The George
Institute of Global Health, UNSW, Sydney.
The aim of the interview is to collect baseline information about your scale up project.
__________________________________________________________________________________

1. Last time you told me about the specific needs of the health for people with hypertension and
diabetes. You stated that ....
a. Has your view changed about the health needs of the community with regard to
hypertension and diabetes?
b. At what stage of the program implementation have you been consulted and in what
manner?
c. What are the benefits that this program offers?
d. Do you think that this model/innovation has been adopted? Do you think that the
community would continue with it?
e. What do you perceive have been their main challenges in the uptake of the program?
f. How have you dealt with these challenges?
2. Tell me a little bit about the front-line staff who will be delivering the program?
a. How important do you think their role is?
b. How often have you kept in touch with them and how?
c. How often would you have liked to keep in touch with them and why?
3. Do you see any challenges to this program for you? What about your community?
****Thank you for your participation *****
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